



FOR ADULTS WITH TARDIVE DYSKINESIA (TD)

Only INGREZZA offers a therapeutic dose from Day 1¹

START AT

40mg




Capsules not actual size

ADJUST IF NEEDED

60mg



80mg



Adjust after 1 week based on response and tolerability.
Recommended dose is 80 mg.



All doses available in capsules and sprinkle formulation

Important Information

INDICATION & USAGE

INGREZZA[®] (valbenazine) capsules and INGREZZA[®] SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington's Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#), including Boxed Warning.



FACILITY  **FRIENDLY DOSING¹**
No titration required
Capsule or sprinkle

No other VMAT2 inhibitor can offer the simplicity of INGREZZA¹

WHY WAIT?



Therapeutic dose from Day 1

WHY TITRATE?




No required titration

WHY OVERCOMPLICATE?




Start with INGREZZA



ONLY INGREZZA offers a sprinkle formulation to treat TD¹

For residents who cannot or choose not to take a pill



Can be sprinkled over soft food

Do not crush or chew INGREZZA SPRINKLE (valbenazine), and do not administer via nasogastric, gastrostomy, or other enteral tubes as it may cause obstruction.

DEUTETRABENAZINE XR/BID is on the DO NOT CRUSH LIST⁵

IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia ($\geq 5\%$ and twice the rate of placebo) is somnolence.

The most common adverse reactions in patients with chorea associated with Huntington's disease ($\geq 5\%$ and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.


Please see accompanying full Prescribing Information, including Boxed Warning.

REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Data on file as of Q3 2024. Neurocrine Biosciences, Inc. 3. Deutetrabenazine [package insert]. Parsippany, NJ: Teva Neuroscience, Inc. 4. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. *Front Neurol.* 2022;13:773999. 5. PharMerica. Oral Medications That Should Not Be Crushed or Altered. October 2024. Accessed May 1, 2025. https://pharmerica.com/wp-content/uploads/2024/10/PMC-DKY-Do-Not-Crush-List-100324_FINAL.pdf.


TD HCP LTC DOSING CARD 2025 SCHEMATIC



Front cover-folded



Inside spread-open



Back cover-folded with pocket on top

Cover, 9” x 9”

ONCE-DAILY

INGREZZA[®]


(valbenazine) capsules

FOR ADULTS WITH TARDIVE DYSKINESIA (TD)

Only INGREZZA offers a therapeutic dose from Day 1¹

START AT


40 mg




Capsules not actual size

ADJUST IF NEEDED


60 mg



80 mg



Adjust after 1 week based on response and tolerability. Recommended dose is 80 mg.



All doses available in capsules and sprinkle formulation

Important Information


INDICATION & USAGE

INGREZZA[®] (valbenazine) capsules and INGREZZA[®] SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington's Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed Warning.



FACILITY FRIENDLY DOSING[™]

No titration required
Capsule or sprinkle

Inside spread, 9” x 18”

ONCE-DAILY

INGREZZA[®]

(valbenazine) capsules

No other VMAT2 inhibitor can offer the simplicity of INGREZZA¹

WHY WAIT?

Therapeutic dose from Day 1

WHY TITRATE?

No required titration

WHY OVERCOMPLICATE?

Start with INGREZZA

WHY WAIT UNTIL DAY 28? | WITH DEUTETRABENAZINE?^{2,3}

Rx

WEEK 1	DAY 1 12	DAY 2 12	DAY 3 12	DAY 4 12	DAY 5 12	DAY 6 12	DAY 7 12
WEEK 2	DAY 8 18	DAY 9 18	DAY 10 18	DAY 11 18	DAY 12 18	DAY 13 18	DAY 14 18
WEEK 3	DAY 15 24	DAY 16 24	DAY 17 24	DAY 18 24	DAY 19 24	DAY 20 24	DAY 21 24
WEEK 4	DAY 22 30	DAY 23 30	DAY 24 30	DAY 25 30	DAY 26 30	DAY 27 30	DAY 28 30

Most patients (52%) were between 36 and 48 mg/day and even 3% were >48 mg/day at the end of long-term study⁴

+Rx WEEK 5

DAY 29 36	DAY 30 36	DAY 31 36	DAY 32 36	DAY 33 36	DAY 34 36	DAY 35 36
--------------	--------------	--------------	--------------	--------------	--------------	--------------

+Rx WEEK 6

DAY 36 42	DAY 37 42	DAY 38 42	DAY 39 42	DAY 40 42	DAY 41 42	DAY 42 42
--------------	--------------	--------------	--------------	--------------	--------------	--------------

+Rx WEEK 7

DAY 43 48	DAY 44 48	DAY 45 48	DAY 46 48	DAY 47 48	DAY 48 48	DAY 49 48
--------------	--------------	--------------	--------------	--------------	--------------	--------------

WHY TITRATE?

Re-titration required for deutetrabenazine following discontinuation or interruption of treatment ≥1 week⁵

Dosing comparison does not imply superiority of efficacy or safety.

For complete dosing information, please refer to each product's Prescribing Information.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.

Somnolence and Sedation

INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.

QT Prolongation

INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Neuroleptic Malignant Syndrome

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.

Parkinsonism

INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed Warning.

Back, 9” x 9”

ONCE-DAILY

INGREZZA[®]

(valbenazine) capsules

FACILITY FRIENDLY DOSING[™]

No titration required
Capsule or sprinkle

ONLY INGREZZA offers a sprinkle formulation to treat TD¹

For residents who cannot or choose not to take a pill

Therapeutic dose from Day 1

Easy to open

3 effective dosing strengths

Once-daily INGREZZA

Take any time of day

Can be sprinkled over soft food

Do not crush or chew INGREZZA SPRINKLE (valbenazine), and do not administer via nasogastric, gastrostomy, or other enteral tubes as it may cause obstruction.

DEUTETRABENAZINE XR/BID is on the DO NOT CRUSH LIST⁵

IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia (≥5% and twice the rate of placebo) is somnolence.


The most common adverse reactions in patients with chorea associated with Huntington's disease (≥5% and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

Please see accompanying full Prescribing Information, including Boxed Warning.

REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Data on file as of Q3 2024. Neurocrine Biosciences, Inc. 3. Deutetrabenazine [package insert]. Parsippany, NJ: Teva Neurosciences, Inc. 4. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. *Front Neurol*. 2022;13:773999. 5. Pharmacia. Oral Medications That Should Not Be Crushed or Altered. October 2024. Accessed May 1, 2025. https://pharmacia.com/wp-content/uploads/2024/10/PMO-DAY-Dose-Not-Crush-List-1003344_FINAL.pdf



©2025 Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US-3994v2 07/2025